Michael Tran, MD
Endocrinology · Anaheim, CANPI 1073552295
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,754 of the $15,860 with a category attached, or 74.1%. It is spread thinly across 43 manufacturers, the largest accounting for just 17.1%.
Across 618 payments — averaging $25.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Applied Medical Resources Corporation$3K
- Medtronic$2K
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- Amgen$982
- Sanofi-aventis U.S. LLC$791
- plus $6K from 37 others
What the payments were for
- Consulting fees$2,62517%
- Travel & lodging$1,4619%
- Food & beverage$11,75474%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,464
- LigaSure$149
- Ozempic$121
- CeQur Simplicity$116
- Kerendia$115
- TOUJEO$113
- SOLIQUA 100/33$105
How this compares
$15,860 in reported general payments places this provider in the 85th percentile of 58 endocrinology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 464 | $438,816 |
| OzempicSemaglutide | 319 | $404,678 |
| JanuviaSitagliptin Phosphate | 156 | $182,969 |
| MounjaroTirzepatide | 94 | $116,765 |
| TrulicityDulaglutide | 77 | $111,346 |
| FarxigaDapagliflozin Propanediol | 64 | $70,202 |
| TradjentaLinagliptin | 71 | $47,790 |
| SynjardyEmpagliflozin/Metformin Hcl | 50 | $47,487 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $44,376 |
| RybelsusSemaglutide | 36 | $40,322 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $28,043 |
| InvokanaCanagliflozin | 26 | $25,418 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $24,417 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $24,116 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 27 | $23,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr, Trijardy Xr | $385 | $601,836649 claims |
| Novo NordiskOzempic, Rybelsus | $1,208 | $444,999355 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,738 | $228,111171 claims |
| MerckJanuvia | $144 | $182,969156 claims |
| AstraZenecaFarxiga | $549 | $70,20264 claims |
| Johnson & JohnsonInvokana | $211 | $25,41826 claims |
| AmgenProlia | $982 | $20,45912 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $791 | $14,00212 claims |
| AbbVieSynthroid | $578 | $12,776127 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $25 | $2,100196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 58 endocrinology providers in California.
Other endocrinology in Anaheim
- Minh MachBurbank$559K
- Joseph HawkinsFresno$477K
- Michael BushBeverly Hills$380K
- Shawna WeislerBurbank$45K
- Ashiq PatelLancaster$32K
- Paul AzerBeverly Hills$25K
- Samuel MayedaOrange$11K
- Daniel KaplanSan Leandro$8K
- Amy van BuiMission Viejo$8K
- Sandeep ChaudharyLaguna Hills$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.